Financial analyst raises share price target for Lundbeck due to Rexulti potential

Lundbeck shares may gain added value, if the firm successfully expands the number of diseases that can be treated with its Rexulti treatment, according to financial services group.
Photo: Jens Dresling
Photo: Jens Dresling

The market is currently underestimating the underlying potential of a couple of Lundbeck's drugs, according to Norwegian financial services group DNB, which raises its share price target to DKK 305 (USD 49.3) from DKK 280 and reiterates its recommendation to buy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading